Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review
| Autor: | Jashin J. Wu, Rima I. Ghamrawi, Neda Ghiam |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Line of therapy media_common.quotation_subject Nice Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Excellence Psoriasis Humans Medicine computer.programming_language media_common 030203 arthritis & rheumatology Biological Products business.industry Anti-Inflammatory Agents Non-Steroidal Treatment options medicine.disease United States Thalidomide Europe Clinical Practice Critical appraisal Family medicine Apremilast business computer medicine.drug |
| Zdroj: | Journal of Dermatological Treatment. 33:94-99 |
| ISSN: | 1471-1753 0954-6634 |
| DOI: | 10.1080/09546634.2020.1770176 |
| Popis: | Purpose: This review article serves to compare global dermatologic organizations and the available clinical practice guidelines for the use of apremilast in the treatment of psoriasis.Materials and methods: Guidelines from the American Academy of Dermatology (AAD), the National Psoriasis Foundation (NPF), the European S3, the National Institute for Health and Care Excellence (NICE), the French Society of Dermatology (SFD), the Swiss S1, and Italy were reviewed and compared.Results: Of the American and European guidelines available for use of apremilast, several organizations are in agreement regarding the dosage of apremilast, but there are significant disagreements concerning matters such as medication indication, pretreatment laboratory testing, and contraindications to therapy.Conclusion: Apremilast is an effective and well-tolerated treatment option for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients, especially those with contraindications to other systemic therapies such as biologics. Consideration should be given to the evidence-based recommendations of global dermatology organizations to help guide therapeutic decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|